Halyard Health (HYH) Receives Average Rating of “Buy” from Analysts

Halyard Health (NYSE:HYH) has been assigned a consensus rating of “Buy” from the eight analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $47.00.

A number of equities research analysts have recently issued reports on HYH shares. Zacks Investment Research cut Halyard Health from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. ValuEngine upgraded Halyard Health from a “hold” rating to a “buy” rating in a report on Wednesday, February 28th. Finally, KeyCorp upgraded Halyard Health from a “sector weight” rating to an “overweight” rating in a report on Thursday, April 5th.

How to Become a New Pot Stock Millionaire

Shares of NYSE:HYH traded down $0.31 during trading on Thursday, reaching $47.95. 230,714 shares of the stock were exchanged, compared to its average volume of 404,191. Halyard Health has a 12 month low of $35.24 and a 12 month high of $50.99. The stock has a market cap of $2,271.40, a PE ratio of 20.40, a P/E/G ratio of 5.67 and a beta of 1.62. The company has a quick ratio of 2.74, a current ratio of 2.98 and a debt-to-equity ratio of 0.45.

Halyard Health (NYSE:HYH) last issued its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.50 by $0.23. Halyard Health had a return on equity of 6.98% and a net margin of 5.82%. The company had revenue of $428.10 million during the quarter, compared to analysts’ expectations of $413.94 million. During the same quarter in the previous year, the company posted $0.50 earnings per share. The business’s revenue was up 4.4% on a year-over-year basis. equities research analysts expect that Halyard Health will post 0.96 earnings per share for the current year.

Several hedge funds have recently modified their holdings of HYH. Channing Capital Management LLC bought a new stake in shares of Halyard Health in the fourth quarter valued at approximately $26,411,000. Macquarie Group Ltd. boosted its stake in shares of Halyard Health by 103.0% in the fourth quarter. Macquarie Group Ltd. now owns 859,281 shares of the medical instruments supplier’s stock valued at $39,681,000 after buying an additional 435,935 shares during the period. Deutsche Bank AG boosted its stake in shares of Halyard Health by 118.8% in the fourth quarter. Deutsche Bank AG now owns 237,641 shares of the medical instruments supplier’s stock valued at $10,971,000 after buying an additional 129,031 shares during the period. Millennium Management LLC boosted its stake in shares of Halyard Health by 107.7% in the fourth quarter. Millennium Management LLC now owns 215,689 shares of the medical instruments supplier’s stock valued at $9,961,000 after buying an additional 111,849 shares during the period. Finally, Allianz Asset Management GmbH boosted its stake in shares of Halyard Health by 193.9% in the fourth quarter. Allianz Asset Management GmbH now owns 158,208 shares of the medical instruments supplier’s stock valued at $7,306,000 after buying an additional 104,386 shares during the period. Institutional investors and hedge funds own 91.34% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/04/19/halyard-health-hyh-receives-average-rating-of-buy-from-analysts.html.

About Halyard Health

Halyard Health, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.

Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply